Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21-Reference-Cited by-同舟云学术

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Published:2016-03-21 Issue:1 Volume:35 Page:
ISSN:1944-446X
Container-title:Chinese Journal of Cancer
language:en
Short-container-title:Chin J Cancer

Author:

Yu Jiang-Yong,Yu Si-Fan,Wang Shu-Hang,Bai Hua,Zhao Jun,An Tong-Tong,Duan Jian-Chun,Wang Jie

Funder

Project supported by the National Natural Sciences Foundation Key Program

Education Ministry Innovative Research Team Program

Peking University-Tsinghua University Joint Center for Life Sciences Clinical Investigator; National High Technology Research and Development Program 863

Beijing Technology Project

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1186/s40880-016-0086-2

Reference26 articles.

1. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–74.

2. Mu XL, Li LY, Zhang XT, Wang MZ, Feng RE, Cui QC, et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin Cancer Res. 2005;11(12):4289–94.

3. Gao G, Ren S, Li A, Xu J, Xu Q, Su C, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int J Cancer. 2012;131(5):E822–9.

4. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(Suppl 1):S24–31.

5. Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 2006;66(16):8163–71.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PER-CRISPR/Cas14a system-based electrochemical biosensor for the detection of ctDNA EGFR L858R;Analytical Methods;2024

2. Silencing of lncRNA LOC105376794 promotes migration, invasion, and gefitinib resistance of lung adenocarcinoma cells with EGFR 19del mutation by ATF4/CHOP axis and ERK phosphorylation;Neoplasma;2024

3. Variant Analysis of miRNA Regulatory Genes in 35 Sporadic Lung Carcinoma Tumors;Doklady Biochemistry and Biophysics;2023-12

4. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301;Journal of Clinical Oncology;2023-09-10

5. Pre-treatment Neutrophil-to-Lymphocyte Ratio significantly affects progression free survival in positive EGFR mutation advanced lung adenocarcinoma with EGFR-TKI treatment in Bali, Indonesia;Romanian Journal of Internal Medicine;2023-03-01